Inflazyme Revises Timeline for Manufacture of Mirococept.VANCOUVER, British Columbia -- Inflazyme Pharmaceuticals Ltd. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :IZP IZP Inorganic Zinc Primer IZP Inter-Zone Path ) announced that it has decided not to proceed with manufacture of cGMP Mirococept(R) (APT070) as previously scheduled in Q1 2005. The Company has taken the decision to defer manufacturing to give it time to complete some additional pre-clinical studies in support of the clinical program. "Mirococept(R) is a new approach to complement inhibition and we therefore want to ensure we have a robust data package to present to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. prior to the commencement of the Phase II clinical program," said Ian McBeath, President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Inflazyme. "Delaying the cGMP manufacture of Mirococept(R) until we are ready to commence clinical trials is financially prudent. We expect to complete these pre-clinical studies in the first half of the year, consequently the Phase II clinical program will not be confirmed until we have the results of these studies." Mirococept(R) is an engineered fragment of the protein sCR1 (soluble complement receptor 1) coupled to Prodaptin(TM), an Inflazyme proprietary drug tethering technology. Prodaptin(TM) is comprised of a peptide motif with a lipophilic lipophilic, adj/n the ability to dissolve or attach to lipids. lipophilic (lipōfil´ik), adj 1. showing a marked attraction to, or solubility in, lipids. 2. tail, which enables tethering to the surface of cells. Since pro-inflammatory complement components are formed and assembled at the cell surface, it is thought that the localization Customizing software and documentation for a particular country. It includes the translation of menus and messages into the native spoken language as well as changes in the user interface to accommodate different alphabets and culture. See internationalization and l10n. of Mirococept(R) increases efficacy while limiting non-specific actions. Mirococept(R) is being investigated in pre-clinical studies for a number of potential acute care inflammatory indications. Inflazyme is a Vancouver based biopharmaceutical company focused on developing new therapies to treat auto-immune and other related diseases. Further information on the Company may be obtained from its website at www.inflazyme.com. Statements in this news release other than historical information are forward-looking statements subject to risks and uncertainties. Actual results could differ materially depending on factors such as the availability of resources, the timing and effects of regulatory actions, the strength of competition, the outcome of litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and the effectiveness of patent protection. Additional information regarding risks and uncertainties is set forth in the current Annual Information Form for Inflazyme on file with the Canadian Securities Commissions. The Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. has not reviewed and does not accept responsibility for the adequacy or accuracy of this information. Inflazyme Pharmaceuticals Ltd. (TSX:IZP) |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion